Canaccord Genuity cuts Clinuvel price target 66% to A$9.52
Canaccord Genuity cut its price target for Clinuvel Pharmaceuticals by 66% to A$9.52 per share, TradingView News reports.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.